CNS Pharmaceuticals Inc. CNSP Archives - Page 20 of 23

FridayDec 18, 2020 8:30 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Hosts Conference Call to Discuss IND Approval, Phase 2 Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, on Thursday announced that it will be holding a conference call to discuss its recently approved Investigational New Drug (“IND”) application involving its lead product candidate Berubicin for the treatment of Glioblastoma Multiforme (“GBM”). The company also intends to discuss its planned Phase 2 Berubicin clinical trial on the call slated for Friday, December 18, 2020 at 8:30 AM ET. Interested parties may access the call by dialing (800) 226-2188 (domestic) or (602) 563-8462 (international)…

ThursdayDec 17, 2020 9:17 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures FDA Approval of IND Application for Brain Cancer Drug Candidate Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, this morning announced that it has received US Food and Drug Administration (“FDA”) approval of its Investigational New Drug (“IND”) application on its lead product candidate Berubicin for the treatment of Glioblastoma Multiforme (“GBM”). This approval signifies a crucial step for the company in launching a potentially pivotal trial to investigate the efficacy of Berubicin in adults with GBM who have been unsuccessful with first-line therapy. In addition, following recent correspondence with the FDA, the…

WednesdayDec 16, 2020 12:17 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Appears on ‘Want Money Got Money’ Podcast

CNS Pharmaceuticals (NASDAQ: CNSP) chairman and CEO John Climaco was featured on a recent “Want Money Got Money” podcast. Hosted by author, founder, speaker and CEO Sam Kamani, the podcast series shares stories, secrets and skills of the world’s most brilliant and interesting start-up founders and investors. During the podcast, Climaco talked about recent research conducted by CNSP founder Dr. Waldemar Priebe that studies the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. In addition, Climaco discussed CNS Pharmaceuticals’ lead drug candidate, Berubicin. The drug is being proposed as a treatment for GBM. A Phase I clinical…

ThursdayDec 10, 2020 12:43 pm

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Brain Cancer Drug IND Filing Accepted for Review by FDA

CNS Pharmaceuticals featured in audio broadcast distributed to thousands of syndication points. Berubicin IND accepted for review by FDA Phase 1 trial showed 44% of patients experiencing clinical benefit of stable disease or better Adult Phase 2 trials to commence in Q1 2021 The IND filing for brain cancer drug Berubicin has been accepted for review by the U.S. Food and Drug Administration (“FDA”), reports CNS Pharmaceuticals (NASDAQ: CNSP), the company now responsible for the drugs’ development. That news was featured in a recent syndicated NetworkNewsAudio (“NNA”) broadcast, which covered CNS Pharmaceuticals’ recent submission of an Investigational New Drug (“IND”)…

WednesdayDec 09, 2020 11:45 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Describes ‘Most Exciting Thing That I’ve Done’ on Gamechangers LIVE

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently appeared on Gamechangers LIVE, a podcast series that shines a spotlight on gamechangers in various industries, sharing perspective on journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. During the interview, CNSP’s chairman and CEO, John Climaco, provided an overview of CNS Pharmaceuticals and its lead drug candidate, Berubicin. Proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer, Berubicin was evaluated in…

TuesdayDec 08, 2020 2:14 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Shines Spotlight on Clinical Design for Upcoming Phase 2 Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, is advancing a drug candidate it hopes will beat the deadly brain cancer Glioblastoma Multiforme (“GBM”). The company recently announced that its submission of an Investigational New Drug (“IND”) application to the U.S. Food & Drug Administration (“FDA”) has been accepted for review and discussed a novel clinical design for its upcoming Phase 2 U.S. trial in a webinar open to the public. “I would like to remind everyone that this upcoming Phase 2…

TuesdayDec 01, 2020 2:36 pm

CNS Pharmaceuticals (NASDAQ: CNSP) Advances Brain Cancer Drug Candidate and Sponsors Annual SNO Conference

Biotechnology developer CNS Pharmaceuticals is preparing, with its partner WPD Pharmaceuticals, a global set of Phase 2 trials for its drug candidate Berubicin, which has shown promise in combating the effectively fatal glioblastoma multiforme (“GBM”) brain cancer Since another company conducted Phase 1 safety trials for Berubicin 14 years ago, one patient has survived cancer-free while two others saw reductions in tumor size of up to 80 percent The Phase 2 trials will build on the Phase 1 results, conducting targeted testing that offers side-by-side comparison between Berubicin and chemotherapy drug lomustine in real time beginning next year The company…

WednesdayNov 25, 2020 10:15 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) IND Application for Cancer Drug Berubicin Accepted for Review

CNS Pharmaceuticals wants to obtain FDA authorization for an Investigational New Drug application for drug candidate Berubicin, a novel treatment for Glioblastoma Multiforme Company believes it’s on track to start in Q1 2021 a potentially pivotal Phase II Berubicin trial with adult GBM patients who have failed their primary treatment for the disease Separately, a Phase II adult trial and a first-ever Phase I pediatric trial are slated to begin in 2021 in Poland in collaboration with sub-licensee partner, WPD Pharmaceuticals Members of CNS’s management team attended A.G.P.’s Virtual Health Symposium, meeting 1-on-1 with investors CNS Pharmaceuticals (NASDAQ: CNSP), a…

TuesdayNov 24, 2020 1:21 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Brain Cancer Drug During Syndicated Broadcast

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, is featured in a recent NetworkNewsAudio (“NNA”) broadcast. During the broadcast, CNS Pharmaceuticals CEO John Climaco explains that the company has recently submitted an investigational new drug (“IND) application to the U.S. Food & Drug Administration (“FDA”) for its brain cancer drug, Berubicin. Climaco also discusses CNSP’s intent to begin Phase 2 trials of the drug during Q1 2021. The Phase 2 trial is designed to analyze the efficacy of Berubicin in treating patients with Glioblastoma…

ThursdayNov 19, 2020 2:11 pm

CNS Pharmaceuticals (NASDAQ: CNSP) Outlines Plans for Advancing Drug It Hopes Will Beat Deadly Brain Cancer

Biotechnology developer CNS Pharmaceuticals is working to advance the clinical trials of a novel brain cancer-fighting drug candidate with the aim of developing a new, effective therapy for treating an otherwise incurable disease The company plans a complex, multi-armed Phase 2 trial of its candidate Berubicin in hopes that the drug candidate may ultimately gain an expedited pathway to approval and registration from the FDA The trial for combatting Glioblastoma Multiforme is expected to begin next year, and on Nov. 12 the company’s officers launched a webinar to provide information on how the trial will be designed CNS Pharmaceuticals is…

Site Search

Company Search

Tag: CNS Pharmaceuticals Inc. CNSP